• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Isis Pharmaceuticals

Isis Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Isis Pharmaceuticals Earns $2M from the Advancement of ISIS -SMN Rx in Children with Spinal Muscular Atrophy

    Isis Pharmaceuticals Earns $2M from the Advancement of ISIS -SMN Rx in Children with Spinal Muscular Atrophy

  2. Isis Pharmaceuticals Initiates Phase 3 Study of ISIS -SMN Rx in Infants with Spinal Muscular Atrophy

    Isis Pharmaceuticals Initiates Phase 3 Study of ISIS -SMN Rx in Infants with Spinal Muscular Atrophy

  3. U.S. considers wider action on Islamist militants

    U.S. considers wider action on Islamist militants

  4. Boehner: Obama lacks 'strategy' against ISIS

    Boehner: Obama lacks 'strategy' against ISIS

  5. EUROPE MARKETS: Stoxx 600 Ends At Almost 3-week High As Tensions Ease

    EUROPE MARKETS: Stoxx 600 Ends At Almost 3-week High As Tensions Ease

  6. UPDATE: Stoxx 600 ends at almost 3-week high as tensions ease

    UPDATE: Stoxx 600 ends at almost 3-week high as tensions ease

  7. EUROPE MARKETS: Stoxx 600 Flirts With 3-week High As Tensions Ease

    EUROPE MARKETS: Stoxx 600 Flirts With 3-week High As Tensions Ease

  8. Stoxx 600 flirts with 3-week high as tensions ease

    Stoxx 600 flirts with 3-week high as tensions ease

  9. Iraqi Military Launches Offensive to Reclaim Tikrit

    Iraqi Military Launches Offensive to Reclaim Tikrit

  10. UPDATE: U.S. stocks rally; Nasdaq eyes highest close in 14 years

    UPDATE: U.S. stocks rally; Nasdaq eyes highest close in 14 years

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.